Screener
Vericel VCEL Biopsy kits — Product sales, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vericel in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Vericel’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:49 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050836
| Revenue by product (in thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Implants subject to third party reimbursement sold through a specialty pharmacy (b) | 5,368 | 2,688 | 10,017 | 5,371 |
| Implants sold direct based on contracted rates (c) | 7,493 | 8,903 | 14,902 | 17,325 |
| Implants sold direct subject to third-party reimbursement (d) | 1,928 | 991 | 3,989 | 2,615 |
| Biopsy kits and instruments - direct bill | 614 | 642 | 1,220 | 1,238 |
| Change in estimates related to prior periods (e) | 211 | 804 | 82 | 1,735 |
| Total MACI implants, kits, and instruments | 65,506 | 53,458 | 121,904 | 99,755 |
| Epicel | ||||
| Direct bill (hospital) | 10,404 | 8,614 | 21,289 | 13,578 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Vericel's biopsy kits — product sales, net?
- Vericel (VCEL) reported biopsy kits — product sales, net of $614K in Q2 2026.
- How has Vericel's biopsy kits — product sales, net changed year-over-year?
- Vericel's biopsy kits — product sales, net decreased by 4.4% year-over-year, from $642K to $614K.
- What is the long-term trend for Vericel's biopsy kits — product sales, net?
- Over 4 years (2021 to 2025), Vericel's biopsy kits — product sales, net has grown at a 4.4% compound annual growth rate (CAGR), from $2.19M to $2.61M.
- What does biopsy kits — product sales, net mean?
- This metric represents the net revenue generated from the sale of biopsy kits used in medical procedures. It reflects the commercial performance and market adoption of the company's diagnostic or procedural hardware offerings within its specialized healthcare portfolio. Tracking this revenue stream helps investors assess the demand for the company's foundational procedural tools and their contribution to overall top-line growth.
Ask your AI about Vericel's biopsy kits — product sales, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude